Viveve to Present at Leerink Global Healthcare Conference

Viveve to Present at Leerink Global Healthcare Conference

Viveve to Present at Leerink Global Healthcare Conference

ENGLEWOOD, CO--(Marketwired - February 09, 2018) - Viveve Medical, Inc. ("Viveve") VIVE, a medical technology company focused on women's intimate health, today announced that Patricia Scheller, chief executive officer and director, will present at the 2018 Leerink Global Healthcare Conference on Thursday, February 15th at 2:00PM ET in New York City. Ms. Scheller will provide an update on the company's global development strategies and commercialization efforts in the United States and abroad.

Event: 2018 Leerink Global Healthcare Conference

Date: February 15, 2018

Time: 2:00 - 2:25 PM ET

Ms. Scheller will be meeting with members of the investment community during one-on-one meetings at the conference. The conference presentation will be webcast live and available for download on the company website at https://ir.viveve.com.

About Viveve

Viveve Medical, Inc. is a women's intimate health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System, that delivers the GENEVEVE™ treatment, incorporates clinically-proven cryogen-cooled, monopolar radiofrequency (CMRF) technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate robust neocollagenesis in a single, in-office session.

International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications from over 55 countries. Consistent with these approvals, Viveve is seeking an Investigational Device Exemption from the U.S. Food and Drug Administration (FDA) to conduct a pivotal study on use of the device for improvement in sexual function. Currently, in the United States, the Viveve System is cleared by the FDA for general surgical procedures for electrocoagulation and hemostasis.

InControl Products by Viveve are FDA cleared medical devices that treat stress, urge, and mixed incontinence conditions and products to improve pelvic floor strength. Viveve exclusively distributes InControl Medical's products to healthcare providers in the United States.

For more information visit Viveve's website at www.viveve.com.

Safe Harbor Statement

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Viveve is a registered trademark of Viveve, Inc.

Geneveve is a trademark of Viveve, Inc.

Investor Relations contact:

Sarah McCabe

Stern Investor Relations, Inc.

(212) 362-1200

sarah@sternir.com



Amato and Partners, LLC

Investor Relations Counsel

admin@amatoandpartners.com



Media contact:


Sara Zelkovic

Berry & Company Public Relations

(212) 253-8881

szelkovic@berrypr.com

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EventsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!